Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients
UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.
Listen to the Contagion Live interview online.
Learn more about the research involving Dr. Becker and Dr. Hite.
Related Stories
The Last Show with David Cooper discusses AI in education with UC’s Joshua Lambert
April 12, 2026
The Last Show with David Cooper, a global news podcast, featured Joshua Lambert, PhD, a professor and biostatistician in UC College of Nursing to discuss his latest research on using artificial intelligence for student advising.
UC enrolls first patients in clinical trial for prosthetic joint infections
April 10, 2026
The University of Cincinnati has enrolled the first patients in Peptilogics’ RETAIN clinical trial, testing an investigational drug for prosthetic joint infections after total knee replacement to reduce repeat surgeries and infection recurrence.
Long before machine guns, ancient Romans used this rapid-fire weapon
April 9, 2026
Smithsonian highlights research by UC Classics Professor Steven Ellis, who supervised archaeological work in the Porta Stabia neighborhood of Pompeii.